Content |
History
2019: Fujifilm purchased from Hitachi business on release of KT-, MRT-and the ultrasonography scanners for $1.63 billion
In the middle of December, 2019 Fujifilm purchased from Hitachi business on release KT- MPT- and ULTRASONOGRAPHY- scanners for $1.63 billion. It is expected that the transaction will be closed in July of the 2020th.
The transaction between two Japanese business giant opens before Fujifilm new opportunities in the industry of visualization researches and will allow to compete to such players as GE Healthcare, Siemens, Philips and Canon on equal terms.
The Fujifilm company specializing in biopharmaceutics and regenerative medicine also made investments in development X-ray technologies, mammographies, a computer tomography, endoscopy and diagnostics of in vitro. The company states that its own technologies of image processing, solution AI of REiLI subsidiary company and also special sales strategy will successfully add the medical equipment of Hitachi.
The Hitachi company, in turn, stated that it will switch attention to global development of systems of cancer therapy on the basis of radiation therapy by the charged particles, diagnostic systems of in vitro, technology of regenerative medicine and also to creation of medical IT platforms. Hitachi expects to get rather high profit as a result of business reorganization.
Fujifilm is going to expand medical division of Hitachi, using own technologies and artificial intelligence and to create the new products promoting quality improvement of medical care.
According to forecasts of Fujifilm, revenue in medical division of the company which includes development of IT solutions for health care will reach 520 billion yens ($4.75 billion) according to the results of the financial year completed at the end of March of the 2020th calendar. The company hopes for growth of volume of this business to 1 trillion yens in the middle of the 2020th years.
Other transactions of Fujifilm in the medical sector in 2019 include investments in the amount of $120 million in production of remedies on the basis of genetic engineering and also acquisition of business on production of biological products at Biogen company for $890 million[1]
2017: Purchase from business Mitsubishi Electric on release of the equipment for radiation therapy
In December, 2017 the Japanese company Hitachi purchased at the compatriot Mitsubishi Electric business on release of the equipment for radiation therapy by the charged particles.
Transaction amount of the party is not disclosed. It is known only that within the agreement signed by the companies business of Mitsubishi will be a part of division of Hitachi Medical Systems. It is supposed to complete absorption in April, 2018, reports DOTmed.com.
 | As both companies pay paramount attention to globalization, we counted for the best to merge assets to achieve competitive advantages and to increase the value of our products due to its improvement. Having an extensive product portfolio for health care, including the equipment for computer and magnetic resonance imaging, ultrasonic diagnostics and radiation therapy by the charged particles, Hitachi considered reasonable from a commercial point to take the lead in this partnership — the head of business in the field of the equipment for radiation therapy of oncological diseases in division of Hitachi Medical Systems commented on Hiroyuki Itami transaction. |  |
Radiation therapy by the charged particles is considered one of the most effective methods of treatment of oncological diseases which is characterized by smaller number collateral effects and faster renewal period, than other methods, such as surgeries.
As of the end of 2017 70 centers of radiation therapy with the charged particles work worldwide. According to forecasts, more than 10 such centers annually will open further.
The transaction opens Hitachi access to technologies and practical experience of Mitsubishi in the field of proton, carbon and hybrid photon and carbon therapy. Hitachi assured that will provide to clients of Mitsubishi the same high level of service as own.[2]
2016
Creation of an incubator of stem cells
At the end of July, 2016 Hitachi presented the special equipment for cultivation of stem cells. It is supposed that the new solution considerably will increase efficiency of transactions on heart and eyes, reports Bloomberg news agency.
The device the size about a cabinet consisting of a set of tubes for a power supply of cages and waste disposal allows to cultivate cages at a certain controlled temperature and humidity.
Development is based on opening of the Nobel Prize laureate on physiology and medicine of 2012 Shinya Yamanaka: it and its command showed that mature cells of skin can be transformed back to stem cells. In addition to Hitachi, experiments with the technology developed by mister Yamanaki are made by the companies Novartis, Roche and Johnson & Johnson.
Before this opening stem cells received from embryos of the person that caused a set of ethical protests and slowed down development of regenerative medicine.
| | The biggest problem which needs to be solved before broad application of regenerative medicine is that is guaranteed to render to all patients treatment and to create technology for large-scale and low-cost production of the high-quality cages suitable for the medical purposes — reported in Hitachi. | |
The Japanese producer claims that the incubator of stem cells which is thought up by him will help to cut down expenses on production and treatment on 1-100 million yens ($1-10 thousand) in a year. According to forecasts of Hitachi, the volume of the world market of regenerative medicine will reach 17 trillion yens ($165.4 billion) by 2030.
The project of Hitachi was supported at the Tokyo women's medical university and the Ministry of Education, by cultures, sport, science and technology of Japan. The cellular incubator was open in the research center Hitachi in June, 2016.[3]
Development of means of the diganostiki of cancer according to the analysis of urine
On June 14, 2016 the producer of the medical solutions Hitachi Medical Systems entering into the Japanese conglomerate Hitachi announced development of the system of simple testing of urine regarding detection of tumoral diseases. The technology is already tested on a small amount of patients and can soon begin to be applied in many medical institutions. For more details see in article Diagnosis of cancer.
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |